<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The nuclear transcription factor NF-kappa B regulates cell survival, proliferation, and differentiation </plain></SENT>
<SENT sid="1" pm="."><plain>Little is known about NF-kappa B in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In this report, we assessed NF-kappa B in a group of myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> by using an electrophoretic mobility shift assay (EMSA) and immunofluorescence methods in freshly isolated <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="3" pm="."><plain>We analyzed 30 cases of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 5 cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), 3 cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>), 15 cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase (<z:mp ids='MP_0005481'>CML</z:mp>-CP), and 2 cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BC) </plain></SENT>
<SENT sid="4" pm="."><plain>Unstimulated cells (bone marrow and peripheral blood) from 17 <z:mpath ids='MPATH_458'>normal</z:mpath> donors and apheresis samples from 6 peripheral blood stem cell donors treated with granulocyte colony-stimulating factor (G-CSF) were used as controls </plain></SENT>
<SENT sid="5" pm="."><plain>When EMSA was used, NF-kappa B was elevated in 14 of 30 (47%) cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, in both cases of <z:mp ids='MP_0005481'>CML</z:mp>-BC, and in <z:hpo ids='HP_0000001'>all</z:hpo> reference donors treated with G-CSF, but it was at basal levels in <z:hpo ids='HP_0000001'>all</z:hpo> cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:mp ids='MP_0005481'>CML</z:mp>-CP and in <z:mpath ids='MPATH_458'>normal</z:mpath> donors (P = &lt;.01) </plain></SENT>
<SENT sid="6" pm="."><plain>Immunofluorescence analysis confirmed strong nuclear RelA/NF-kappa B immunoreactivity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> blasts but not in <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow </plain></SENT>
<SENT sid="7" pm="."><plain>Bcl-2, a downstream molecule, was expressed in cases with elevated NF-kappa B, but not in cases with basal levels of NF-kappa B, suggesting that NF-kappa B is active and provides the cells with survival advantages in vivo </plain></SENT>
<SENT sid="8" pm="."><plain>These results suggest that suppression of NF-kappa B may be a useful therapeutic strategy for a subset of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>